PHAXIAM Therapeutics S.A. (PHXM.PA)
EUR 0.31
(-27.91%)
EUR 0.31
(-27.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.93 Million EUR | 32.65% |
| 2022 | 3.07 Million EUR | 47.26% |
| 2021 | -49.38 Million EUR | 18.12% |
| 2020 | -69.41 Million EUR | -3.71% |
| 2019 | -60.82 Million EUR | -37.8% |
| 2018 | -41.77 Million EUR | -40.17% |
| 2017 | -33 Million EUR | -30.79% |
| 2016 | -24.9 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.27 Million EUR | 0.0% |
| 2024 Q1 | -5.27 Million EUR | -221.63% |
| 2023 Q3 | -5.48 Million EUR | 55.81% |
| 2023 Q1 | -3.94 Million EUR | 42.9% |
| 2023 FY | - EUR | 18.39% |
| 2023 Q4 | -1.64 Million EUR | 70.08% |
| 2023 Q2 | -12.41 Million EUR | -214.4% |
| 2022 Q2 | -20.92 Million EUR | 0.0% |
| 2022 Q4 | -6.91 Million EUR | -47.08% |
| 2022 Q3 | -4.7 Million EUR | 77.52% |
| 2022 FY | - EUR | 47.26% |
| 2021 Q2 | -28.74 Million EUR | 0.0% |
| 2021 Q4 | -26.57 Million EUR | 0.0% |
| 2021 FY | - EUR | 18.12% |
| 2020 Q4 | -32.85 Million EUR | 0.0% |
| 2020 FY | - EUR | -3.71% |
| 2020 Q2 | -34.78 Million EUR | 0.0% |
| 2019 Q4 | -33.02 Million EUR | 0.0% |
| 2019 FY | - EUR | -37.8% |
| 2018 FY | - EUR | -40.17% |
| 2017 FY | - EUR | -30.79% |
| 2016 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | -41.212% |
| European Medical Solutions | 59 Thousand EUR | 38964.407% |
| FERMENTALG | -10.51 Million EUR | -118.173% |
| argenx SE | -199.5 Million EUR | 88.507% |
| BioSenic S.A. | -6.79 Million EUR | -237.404% |
| Celyad Oncology SA | -7.76 Million EUR | -195.375% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -53.071% |
| Onward Medical N.V. | -35.23 Million EUR | 34.921% |
| Oxurion NV | -16.72 Million EUR | -37.067% |
| Financière de Tubize SA | 184.57 Thousand EUR | 12523.403% |
| UCB SA | 1.26 Billion EUR | 101.807% |